louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06073262: Investigation of Low Back Pain Level on Symptoms in Chronic Consipation
Official title: Investigation of the Effect of Low Back Pain Level on Symptoms in Individuals With Chronic Consipation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Low Back Pain
Constipation
Keywords: pain
Low Back Pain
Constipation
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2023-10-10
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In this study, Rome III diagnostic criteria, which is the most commonly used diagnostic method, will be used to determine constipation status. According to the Rome III diagnostic criteria, the following symptoms must have been present for the last 3 months and these symptoms must have started at least 6 months before the diagnosis.

Brief summary: Consipation is the most common digestive complaint in the general population

Detailed description: Chronic constipation and low back pain are two common and often co-existing health conditions that affect millions of people worldwide. On the surface, these conditions appear to be unrelated and are associated with different anatomical sites (gastrointestinal tract and musculoskeletal system). However, a growing body of research is beginning to shed light on the complex interplay between chronic constipation and low back pain, highlighting potential links between these seemingly disparate health conditions. Common etiologic factors such as neuromuscular function, chronic inflammation and lifestyle-related variables are known to exist

Eligibility criteria: Inclusion Criteria:

* 18-65 ages
* Rome III diagnostic criteria

Exclusion Criteria:

* Severe heart or kidney diseaseprevious gastrointestinal, spinal or pelvic surgery other than cholecystectomy, hysterectomy or appendectomy neurological diseases such as
* Multiple sclerosis, stroke, Parkinson's disease or spinal injury,
* Impaired awareness (mini-mental score \< 15),
* Legal blindness, pregnancy,
* Rectal prolapse
* Anal fissure and altered constipation and diarrhea pattern.

Primary outcomes:
measure: Bristol Stool Scale
timeFrame: one day
measure: Pelvic Pain Impact Questionnaire
timeFrame: one day
measure: Constipation Severity Scale
timeFrame: one day
measure: Disability level
timeFrame: one day
measure: Autonomic nervous system device (Polar H10)
timeFrame: one day
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: HAZAL genç
state: None Selected
Study officials:
References:
Clinical trial NCT05258162: Comparison of Mobilization and MET Post-Traumatic Elbow Stiffness
Official title: Comparison of Mobilization and Muscle Energy Technique in Patients With Post-Traumatic Elbow Stiffness
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Elbow Fracture
Keywords: Post Traumatic Elbow Stiffness
Pain
Elbow
Disability
Fracture
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-02-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find the effects of Mobilization and Muscle energy technique in patients with post-traumatic elbow stiffness.

Detailed description: A randomized control trial was conducted at Benazir Bhutto Hospital, Rawalpindi. The sample size with reference to parent article was 10 calculated through open epi tool. But 30 patients were included in the study to increase the statistical power of analysis. The participants were divided into two interventional groups i.e. Group A and Group B, each having 15 participants. The study duration was 1 year. Sampling Technique applied was non probability purposive sampling technique. Random Allocation will be through sealed envelope method into two treatment group i.e. Group A and Group B. Only 18-35 years old patients (both male and female) with Post-traumatic elbow stiffness were included in the study. Tools that were used in the study are NPRS, DASH questionnaire, TAMPA scale and Goniometer. Total duration of treatment for both groups was 3 weeks, 3 days a week. Pre and post assessment was done. Data was analyzed through SPSS version 23.

Eligibility criteria: Inclusion Criteria:

* Patients with post-operative elbow stiffness after distal end extra-articular humerus fractures.
* Patients with proximal radius ulna fractures.
* Minimum immobilization period of 3 weeks

Exclusion Criteria:

* Any ligament injury
* Patients with Diabetes
* Patients with RA
* Patients with Pathological fractures
* Revision surgeries
* Neuro-vascular disorders.

Primary outcomes:
measure: Numeric pain rating scale
timeFrame: 3rd week
measure: ROM Elbow (Flexion)
timeFrame: 3rd week
measure: ROM Elbow (Extension)
timeFrame: 3rd week
measure: ROM Forearm (Supination)
timeFrame: 3rd week
measure: ROM Forearm (Pronation)
timeFrame: 3rd week
Secondary outcomes:
measure: Disability
timeFrame: 3rd week
measure: kinesiophobia (fear of movement)
timeFrame: 3rd week
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Benazir Bhutto Hospital
state: Punjab
Study officials:
affiliation: Riphah International University
name: Muhammad Affan Iqbal, PhD*
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06697262: Impact of a Telemonitoring Device on the Occurever at Home in Children at Risk of Chemotherapy-Induced Neutropenia
Official title: Impact of a Telemonitoring Device on the Occurrence of Fever at Home in Children at Risk of Chemotherapy-Induced Neutropenia: A Pilot Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Oncopediatrics
Febrile Neutropenia
Lead sponsor: Centre Hospitalier Universitaire de la Réunion
Sponsor class: OTHER
First posted: 2024-11-20
Enrollment: 30
Sex: ALL
Minimum age (years): 0
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to evaluate the feasibility of the study, measured by the acceptability rate of patients to be recruited in a study proposing temperature monitoring at home, by a remote monitoring device or by the visit of an IDE at home (in association with the usual educational sessions), to children at risk of febrile neutropenia, from families with psycho-social vulnerabilities.

The main questions it aims to answer are:

* Will participants adhere to the telemonitoring system?
* Is the intervention feasible, in terms of the device's failure to record temperature data?
* Will parents behave appropriately when using the device?
* How satisfied will parents and caregivers be?
* What will be the physical tolerance of the device?
* On an exploratory basis, will the remote monitoring system be effective for months?

Researchers will compare :

* patients using the telemonitoring device for continuous temperature monitoring at home, in combination with education sessions on temperature monitoring and the device
* with patient with temperature monitoring at home by a nurse, 2 times a day, in combination with education sessions on temperature monitoring (without the telemonitoring device at home)


Eligibility criteria: Inclusion Criteria:

patient

* Aged 0 to 17 inclusive
* Followed in the Pediatric Onco-Hematology Department
* Primo-diagnosed with solid or hematological cancer (incident case)
* Having received a first cycle of chemotherapy
* Whose family has psycho-social vulnerabilities assessed by the Froger et al. tool, indicating a need for an IDE to support the family in monitoring the patient.

Exclusion Criteria:

Patient:

* with a dermatosis contraindicating the use of the device
* Refusing to participate in the study

Primary outcomes:
measure: study acceptability rate
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05518162: Treatment of Post-partum Depression Using an Behavioral Intervention Called ROSE (Reach Out, Stay Strong, Essentials for Mothers of Newborns) Delivered Using an Electronic App
Official title: InBloom App Vs ROSE Outcomes and Mechanisms
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Post-partum Depression
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2022-08-26
Enrollment: 152
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized trial of pregnant people at risk for postpartum depression comparing the InBloom app (n = 76) to ROSE (n = 76; weekly scheduled group), and two control groups. We will assess Depression at baseline and 1, 2 and 3 months, ROI at 3 months, Satisfaction at 1 and 3 months and Perceived Access at 1 and 3 months. Subject participation will last up to 8 months (minimum 17 weeks pregnant through 3 months postpartum).


Eligibility criteria: Inclusion Criteria:

* 17-32 weeks pregnant
* enrolled for prenatal care in one of the five identified practices
* English speaking
* able to use an app (audio/visual/dexterity)
* have one or more of the following PPD risk factors: Medicaid eligible; anxiety (GAD-7 \> 10) during pregnancy; mild to moderate depressive symptoms (PHQ-9 = 10-19); self-reported history of depression treatment; gestational diabetes; and/or young age (18-21 years).

Exclusion Criteria:

* patients with acute mental health needs
* cannot communicate in English
* demonstrate significant cognitive impairment
* are planning to place the child for adoption
* PHQ-9 depression score \> 19
* younger than age 18

Primary outcomes:
measure: proportion of participants with post-partum depression assessed using the Mini International Neuropsychiatric Interview (MINI)
timeFrame: 3 months
measure: mean depression severity measured using Patient Health Questionnaire (PHQ-9)
timeFrame: baseline
measure: mean depression severity measured using Patient Health Questionnaire (PHQ-9)
timeFrame: 1 month
measure: mean depression severity measured using Patient Health Questionnaire (PHQ-9)
timeFrame: 2 months
measure: mean depression severity measured using Patient Health Questionnaire (PHQ-9)
timeFrame: 3 months
Secondary outcomes:
measure: Return on Investment (ROI)
timeFrame: 3 months
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester Medical Center
state: New York
Study officials:
References:
Clinical trial NCT05237362: Saga Stories in Health Talks in Primary Child Healthcare
Official title: An Effectiveness-implementation Hybrid Trial to Evaluate a Health Promotion Intervention Within Swedish Primary Child Healthcare: Saga Stories in Health Talks
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Self Efficacy
Keywords: Health promotion
Primary child healthcare
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2022-02-14
Enrollment: 763
Sex: ALL
Minimum age (years): 5
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Primary child healthcare in Sweden is an important arena for health promotion interventions as nurses regularly meet parents and children from birth to five years of age. To date there is a lack of evidence-based material for child healthcare nurses to use in health promotion talks within primary child healthcare. Therefore, the aims of this study are to: (i) evaluate the effectiveness of Saga Stories in health talks on parental self-efficacy to promote healthy diet, physical activity, and screen time behaviours in 5-year-old children and (ii) evaluate the implementation of Saga Stories in health talks with regards to acceptability, appropriateness, feasibility, fidelity, adoption, sustainability, satisfaction, and usage.


Eligibility criteria: Inclusion Criteria:

* The parent the accompanies the child to the 5-year check-up at primary child healthcare needs to be able to understand Swedish sufficiently well in order to provide informed consent and partake in the Saga Stories health talk.

Exclusion Criteria:

* None

Primary outcomes:
measure: Self-efficacy
timeFrame: At the end of the intervention which is two months after baseline
Secondary outcomes:
measure: Intake of key dietary indicators as assessed by a questionnaire
timeFrame: At the end of the intervention which is two months after baseline
measure: Screen time as assessed by a questionnaire
timeFrame: At the end of the intervention which is two months after baseline
measure: Acceptability
timeFrame: 3 months after implementation
measure: Appropriateness
timeFrame: 3 months after implementation
measure: Feasibility of implementing Saga Stories
timeFrame: 3 months after implementation
measure: Change in the fidelity of the Saga Stories intervention
timeFrame: 2, 4, 6, 8, 10, and 12 months after implementation
measure: Change in the adoption of the Saga Stories intervention
timeFrame: 2, 4, 6, 8, 10, and 12 months after implementation
measure: Sustainability
timeFrame: One year after implementation
measure: Parental satisfaction and usage of Saga Stories
timeFrame: Post-intervention (i.e., 2 months after baseline assessment)
Other outcomes:
Locations:
city: Huddinge
country: Sweden
facility: Department of Biosciences and Nutrition, Karolinska Institutet
Study officials:
References:
Clinical trial NCT01493362: Imaging the Dopamine Systems in Bulimia Nervosa
Official title: Imaging the Dopamine Systems in Bulimia Nervosa
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eating Disorders
Keywords: Bulimia Nervosa
PET Imaging
Dopamine
Lead sponsor: New York State Psychiatric Institute
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2011-12-16
Enrollment: 33
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will include people with bulimia nervosa seeking inpatient or outpatient treatment and people who will act as healthy control participants

Brief summary: This study will use positron emission tomography imaging to investigate the dopamine systems in people with bulimia nervosa.


Eligibility criteria: Inclusion Criteria:

Participants with BN:

* Meets DSM-IV criteria for BN
* Sufficiently medically and psychiatrically stable to participate in research

Health Control Participants:

* No current or past psychiatric illness
* Between 80% and 120% of ideal body weight

Exclusion Criteria:

All participants:

* Current use of psychotropic medication such as anti psychotics or antidepressants
* Pregnant or breastfeeding
* history of substance abuse
* Significant medical illness
* High blood pressure (resting systolic blood pressure greater than 150mmHg and diastolic blood pressure greater that 90 mmHg)
* Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder as defined by DSM-IV
* Metal implants or paramagnetic objects contained within the body that may interfere with the MRI scan, as determined in consultation with a neuroradiologist and according to specified reference book guidelines
* Exposed to radiation in the workplace or has had a nuclear medicine procedure during the 1 year before study entry
* Previous adverse reaction to psycho stimulants

Primary outcomes:
measure: D2 receptor density
timeFrame: Measured at baseline
measure: DA release in the striatum
timeFrame: Measures after Mythlyphenidate challenge
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York State Psychiatric Institute
state: New York
Study officials:
References:
Clinical trial NCT04951362: Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia
Official title: Studying the Expected Effect of Ivermectin Nanosuspension as Nasal Spray Upon Post covid19 Persistant Anosmia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Anosmia
Lead sponsor: South Valley University
Sponsor class: OTHER
First posted: 2021-07-06
Enrollment: 117
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

Detailed description: ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia as one of the most characteresic symptoms of covid19 infection

Eligibility criteria: Inclusion Criteria:

* post covid19 anosmia
* negative swab test for covid19

Exclusion Criteria:

* other types of anosmia ,
* no local or central other causes of anosmia
* still active covid 19 pateints ( positive swab test )

Primary outcomes:
measure: regaining of smell
timeFrame: within 14 days after enrollemen ]
Secondary outcomes:
Other outcomes:
Locations:
city: Qina
country: Egypt
facility: Zaky Aref
Study officials:
References:
citation: Aref ZF, Bazeed SEES, Hassan MH, Hassan AS, Ghweil AA, Sayed MAA, Rashad A, Mansour H, Abdelmaksoud AA. Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia. Infect Drug Resist. 2022 Sep 19;15:5483-5494. doi: 10.2147/IDR.S381715. eCollection 2022.
Clinical trial NCT01599962: Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects
Official title: Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Memory Functions
Lead sponsor: University of Basel
Sponsor class: OTHER
Collaborators: name: Clinical Trial Unit, University Hospital Basel, Switzerland
First posted: 2012-05-16
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: To investigate the effects of the calcimimetic agent cinacalcet on cognitive functions in healthy humans.


Eligibility criteria: Inclusion Criteria:

* healthy
* normotensive
* native or fluent German-speaking
* caucasian (European ancestry)
* BMI between 19 and 27 kg/m2

Exclusion Criteria:

* acute or chronic psychiatric or somatic disorder
* pathological ECG
* Low serum calcium
* known hypersensitivity to the IMP
* pregnancy
* breast-feading
* long-term medication within last 3 months
* smoking more than 3 cigarettes per day
* seizures in participants and first degree relatives
* concurrent participation in another study

Primary outcomes:
measure: Change of attention functions under cinacalcet
timeFrame: two study days within 10 days
measure: Change of memory functions under cinacalcet
timeFrame: two testing days within 10 days
Secondary outcomes:
measure: Change of emotional state under cinacalcet
timeFrame: two study days within 10 days
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University of Basel, Division of Cognitive Neuroscience
Study officials:
affiliation: University of Basel
name: Dominique de Quervain, Prof. MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01476462: Second Malignant Neoplasms After Childhood ALL Therapy
Official title: Second Malignant Neoplasms After Childhood ALL Therapy; An International Ponte di Legno Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Lymphoblastic Leukemia
Keywords: Acute lymphoblastic leukemia
Ponte-di-Legno consortium
Second cancer
Survival
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Nordic Society for Pediatric Hematology and Oncology
name: European Organisation for Research and Treatment of Cancer - EORTC
name: Dana-Farber Cancer Institute
name: ALL-BFM Study Group
name: Dutch Childhood Oncology Group
name: St. Jude Children's Research Hospital
name: United Kingdom Children's Cancer Study Group
First posted: 2011-11-22
Enrollment: 642
Sex: ALL
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study cohort includes all registered cases of second cancers occurring as the first event among children diagnosed with acute lymphoblastic leukemia and treated according to protocol by one of the collaborative groups participating in the present study

Brief summary: Development of a second neoplasm (SMN) during or after therapy for childhood acute lymphoblastic leukemia (ALL) is a rare event generally associated with a poor prognosis. In this international study we analyze subtypes of SMN in relation to their initial leukemia characteristics and treatment, and their subsequent overall survival.

Detailed description: To explore epidemiology, potential risk factors and survival rates of second cancers occurring as the first event in childhood acute lymphoblastic leukemia the involved study groups will collect anonymous data on all such cases diagnosed within the last decades to form a common database with predefined variables comprising the clinical, biological, and cytogenetic characteristics (myeloid neoplasias only) as well as outcome. Furthermore, we will register the clinical, biological, and cytogenetic characteristics of the acute lymphoblastic leukemia as well as type of treatment given.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with childhood acute lymphoblastic leukemia
* Diagnosis of second cancer before December 31st 2007

Exclusion Criteria:

* Uncertainty if the second cancer has emerged from the same original leukemic clone

Primary outcomes:
measure: Pattern of SMN subtypes
timeFrame: At 20 years from diagnosis
measure: Overall survival by subtype
timeFrame: At 10 years from diagnosis of SMN
measure: Risk factors for development of SMN
timeFrame: At 20 years from ALL diagnosis
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Kjeld Schmiegelow
Study officials:
affiliation: Rigshospitalet, Denmark
name: Kjeld Schmiegelow, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Dipartimento di medicina clinica e prevenzione, University of Milan, Italy
name: Maria G Valsecchi, M.Sci,
role: PRINCIPAL_INVESTIGATOR
References: